Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)

Edwin Choy, Karla Ballman, James Chen, Mark A. Dickson, Rashmi Chugh, Suzanne George, Scott Okuno, Raphael Pollock, Rajiv M. Patel, Antje Hoering, Shreyaskumar Patel

Research output: Contribution to journalComment/debate

Abstract

In the article titled "SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy" [1], the second author, Dr. Ballman, was paid by Lilly and only recently realized that gemcitabine is a Lilly product and apologizes for not declaring this sooner.

Original languageEnglish (US)
Article number7608743
JournalSarcoma
Volume2019
DOIs
StatePublished - 2019

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Corrigendum: sARC018_SPORE02: Phase II study of mocetinostat administered with gemcitabine for patients with metastatic leiomyosarcoma with progression or relapse following prior treatment with gemcitabine-containing therapy (Sarcoma (2018) 2018 (2068517) DOI: 10.1155/2018/2068517)'. Together they form a unique fingerprint.

  • Cite this